Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Status:
Completed
Trial end date:
2019-03-09
Target enrollment:
Participant gender:
Summary
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential
participant.
The goal of this clinical research study is to learn if thiotepa, busulfan, and clofarabine,
when given before an allogeneic (bone marrow , blood, or cord blood cells) or haploidentical
(bone marrow) stem cell transplantation can help to control cancers of the bone marrow and
lymph node system. The safety of this treatment will also be studied.
This is an investigational study. Thiotepa and clofarabine are FDA approved and commercially
available for the treatment of leukemia. Busulfan is FDA approved and commercially available
for use in stem cell transplantation. The combination of thiotepa, clofarabine, and busulfan
together with a stem cell transplant is investigational.
Up to 60 participants will take part in this study. All will be enrolled at M. D. Anderson.